Guidance Update

SHIRE PLC - Guidance Update

PR Newswire

London, January 8

Guidance Update

Dublin, Ireland - January 8, 2013 - Shire plc (LSE: SHP, NASDAQ: SHPG)

Angus Russell, Chief Executive Officer of Shire, will address investors todayat the JP Morgan Healthcare Conference in San Francisco. In his address he willconfirm that Shire expects to deliver double digit full year earnings growthfor 2012, and looking ahead, Shire is now increasingly confident of meetingcurrent consensus earnings expectations(1) for 2013.

Angus' presentation will be webcast live today, at 11:00 AM PST/2:00 PM EST/7:00 PM GMT

(1) Based on the most recent consensus estimates compiled by Consensus ForecastLtd, as of the date of this press release, of $6.69 Non GAAP diluted earningsper ADS for the year ended 31 December 2013, included on Shire's website (http://www.shire.com/shireplc/en/investors/forecasts).

For further information please contact:

Shire enables people with life-altering conditions to lead better lives.

Through our deep understanding of patients' needs, we develop and providehealthcare in the areas of:

as well as other symptomatic conditions treated by specialist physicians.

We aspire to imagine and lead the future of healthcare, creating value forpatients, physicians, policymakers, payors and our shareholders.

"SAFE HARBOR" STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF1995

Statements included herein that are not historical facts are forward-lookingstatements. Such forward-looking statements involve a number of risks anduncertainties and are subject to change at any time. In the event such risks oruncertainties materialize, the Company's results could be materially adverselyaffected. The risks and uncertainties include, but are not limited to, risksassociated with: the inherent uncertainty of research, development, approval,reimbursement, manufacturing and commercialization of the Company's SpecialtyPharmaceuticals, Human Genetic Therapies and Regenerative Medicine products, aswell as the ability to secure new products for commercialization and/ordevelopment; government regulation of the Company's products; the Company'sability to manufacture its products in sufficient quantities to meet demand;the impact of competitive therapies on the Company's products; the Company'sability to register, maintain and enforce patents and other intellectualproperty rights relating to its products; the Company's ability to obtain andmaintain government and other third-party reimbursement for its products; andother risks and uncertainties detailed from time to time in the Company'sfilings with the Securities and Exchange Commission.

www.shire.com